Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Immunotactoid glomerulopathy


See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Prognosis

Newline Maker

What is the long-term prognosis for immunotactoid glomerulopathy?

The long-term prognosis for immunotactoid glomerulopathy is difficult to predict due to the rarity of the condition, but some studies suggest that 50% of patients will have end-stage kidney disease (ESKD) by 5 years after diagnosis. Patients with ESKD may either pursue dialysis or kidney transplantation. The disease may recur in the transplanted kidney. However, the degree and rate of recurrence remains unclear due to the rarity of this disease. Researchers believe the rate of progression of the disease in the transplanted kidney is slower than in the native kidney. The rate of recurrence seems to be higher in patients who have monoclonal gammopathy.[1][2]
Last updated: 3/28/2014

References
  1. Immunotactoid Glomerulopathy. UNC Health Care Kidney Center. http://www.unckidneycenter.org/kidneyhealthlibrary/immunotactoid.html. Accessed 3/28/2014.
  2. Fervenza F, Sethi S, Appel G. Glomerular diseases due to nonamyloid fibrillar deposits. UpToDate. September 30, 2013; http://www.uptodate.com/contents/glomerular-diseases-due-to-nonamyloid-fibrillar-deposits. Accessed 3/28/2014.


See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.